Alaxia - Eveon - DTF

The ALIPEX development program seeks to provide cystic fibrosis (CF) patients with a new-generation inhalation treatment efficient in fighting severe respiratory infections, including those resistant to antibiotics.

This treatment, based on three major innovations, respectively developed by three companies in France's Rhône-Alpes region – ALAXIA, EVEON and DTF Medical – benefits from the collaboration with two research laboratories.

The ALIPEX development program has been granted support from Bpifrance, as part of its Strategic Industrial Innovation program, asserting the potential of this major therapeutic and technological breakthrough, with possible applications beyond the treatment of this rare disease (CF).

rare disease day28 February 2014 marks the seventh international Rare Disease Day coordinated by EURORDIS. On and around this day hundreds of patient organisations from more than 70 countries and regions worldwide are planning awareness-raising activities around the slogan "Join Together for Better Care".

OI-Net - Open Innovation European net work

The OI-Net website has been launched in January 2014 for the Open Innovation European network supported by the ERASMUS programme.

MAC-Team is in charge of the design an deployment of the website, which includes a social network, a forum, an event registration system, a survey engine and many other functions.

Right after one month, the European OI-Net community registered is already 100 people!

ISPIMISPIM XXVth conference - "Innovation for Sustainable Economy and Society" - 8-11 June 2014, Dublin, Ireland

+ a presentation paper by MAC-Team at the conference in the section on "Innovation for Sustainable and Inclusive Growth".

  The RISKY Knowledge project is now finished following the last transnational meeting done in Madrid on 2013, November 20th.